Trial Profile
Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 May 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal detachment
- Focus Therapeutic Use
- Acronyms EVEN
- 26 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov
- 26 May 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov
- 26 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov